Goldman A, Malpas J S
Cancer Chemother Pharmacol. 1982;9(1):53-6. doi: 10.1007/BF00296763.
Twenty-nine children with tumours that had failed to respond to conventional therapy have been treated with AMSA. There were 16 patients with haematological malignancies in whom treatment was initiated at 25 mg/m2 for 3 days, increasing to 150 mg/m2 for 5 days. There were one complete and four partial remissions in these patients, all of whom had received at least 500 mg AMSA/m2. Thirteen children with solid tumours were treated. They received single doses of 120 mg/m2 initially, increasing to 100 mg/m2 for 5 days. No complete or partial responses occurred, but some antitumour activity was noted in neuroblastoma and retinoblastoma. Dose-related severe bone marrow toxicity occurred, but gastrointestinal and other toxicity was mild. An additional patient with T cell lymphoma, who received AMSA prior to a successful autologous bone marrow transplant, is described. AMSA is an active drug in childhood leukaemia. Further studies at the maximum tolerated dose are needed to assess enough patients with any single solid tumour type. In particular, the response of neuroblastoma warrants further study. Investigation of the use of AMSA either prior to bone marrow transplantation in leukaemia or in association with autologous marrow transplant in neuroblastoma and other solid tumours may be of value.
29名对传统疗法无反应的肿瘤患儿接受了氨苯吖啶（AMSA）治疗。其中16例血液系统恶性肿瘤患者，治疗起始剂量为25mg/m²，持续3天，然后增至150mg/m²，持续5天。这些患者中有1例完全缓解，4例部分缓解，所有患者接受的氨苯吖啶剂量均至少达到500mg/m²。13名实体瘤患儿接受了治疗。他们最初接受单剂量120mg/m²，然后增至100mg/m²，持续5天。未出现完全或部分缓解情况，但在神经母细胞瘤和视网膜母细胞瘤中观察到了一些抗肿瘤活性。出现了与剂量相关的严重骨髓毒性，但胃肠道及其他毒性较轻。还描述了1例T细胞淋巴瘤患者，该患者在成功进行自体骨髓移植前接受了氨苯吖啶治疗。氨苯吖啶在儿童白血病中是一种活性药物。需要在最大耐受剂量下进行进一步研究，以评估足够数量的单一实体瘤类型患者。特别是，神经母细胞瘤的反应值得进一步研究。研究氨苯吖啶在白血病骨髓移植前或与神经母细胞瘤及其他实体瘤的自体骨髓移植联合使用可能具有价值。
